The demand graph of the global chronic kidney disease (CKD) drugs market is treading along a lucrative track. The importance of healthy kidneys for the human body cannot be underestimated. The kidneys are not only an important body organ, but also a part of the larger human anatomy responsible for several functions. The functions of the kidney in the human body span into several areas of nephrology. Furthermore, kidney disorders can damage several functionalities in the human body. It is safe to assert that several functions of the human body rely on healthy subsistence of the kidneys. It is a matter of attention that kidney failure cannot be reversed, and only a healthy kidney can help restore the corresponding functionalities. Therefore, the total volume of revenues within the global chronic kidney disease (CKD) drugs market is set to rise.

In this report preview, Transparency Market Research furnishes several important trends and propensities that have aided the expansion of the global chronic kidney disease (CKD) drugs market. Furthermore, constant dialysis also necessitates the use of important drugs that can complement the process. Over the course of the next decade, the global chronic kidney disease (CKD) drugs market is set to attract fresh investments. The focus of the healthcare industry on collaborating with drug development entities has given an impetus to market maturity.

chronic kidney disease drugs market

Severity of Symptoms of CKD

Several symptomatic tendencies are related to the occurrence of chronic kidney disorders. Kidneys play an important role in ensuring timely and healthy urination, and this functionality is disrupted in the case of diseases kidneys. Furthermore, kidney disorders can disturb the sleeping and eating routines of the masses, creating new opportunities for growth across the global chronic kidney disease (CKD) drugs market. Several new drugs to treat kidney disorders have been developed in recent times. This trend shall cause an uptick in demand across the chronic kidney disease (CKD) drugs market.

Rising Geriatric Population to Drive Demand

A large geriatric population suffers from kidney disorders that can cripple them of basic functioning. Regular dialysis helps these individuals in experiencing temporary relief from kidney and urinal pain. However, it is important to develop drugs that can support patients who do not resort timely dialysis. The occurrence of chronic kidney disease (CKD) in youngsters can be a source of pain and discomfort. Therefore, the use of chronic kidney disease (CKD) drugs in this population group shall rise in the years to follow. Several medical research institutes have recommended new drug formulae for the treatment of kidney disorders.

Importance of Timely Treatment

Chronic kidney diseases can be a source of several other problems such as puffiness of eyes. Inconsistent sleeping patterns, urinary pain, skin irritation, and swollen ankles. Therefore, it is imperative for medical practitioners to ensure kidney disorders are treated and controlled at the earliest. The humongous importance of chronic kidney disease (CKD) drugs post dialysis has given a thrust to market growth. The next decade would be crucial in deciding the growth direction of the global chronic kidney disease (CKD) drugs market.

Growth of North America Market

On the basis of geography, several new regions have acquired fruition in the chronic kidney disease (CKD) drugs market. The healthcare sector of the US has acquired fresh revenues in recent times, mainly due to the inflow of fresh investments. The focus on treating kidney disorders, especially for the geriatric population, has played a vital role in market growth and maturity.

Some of the notable players who have made a mark in the global chronic kidney disease (CKD) drugs market are F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi S.A., GlaxoSmithKline Plc, Kissei Pharmaceutical Co. Ltd., and AbbVie Inc.

Rising Cases due to Changes in Lifestyle Habits will accelerate the Growth Prospects of the Chronic Kidney Disease Drugs Market

The chronic kidney disease drugs market will observe profitable growth across the assessment period of 2016-2024. The lifestyle habits of many individuals have changed substantially over time. Hectic schedules and busy routines have resulted in heightened stress levels, which are giving rise to the consumption of alcohol and other addictive substances. Kidney failures are largely caused due to smoking, hypertension, and other aspects. The rapidly changing habits in regards to addictive substances as well as food consumption and the escalating rise in the cases will accelerate the growth prospects of the chronic kidney disease drugs market.

  • Chronic kidney diseases can be described as the eventual loss of kidney functions. The kidneys cannot function in a smooth way, that is, they can’t filter the blood as per their normal capacity. Controlling the rising cases is the need of the hour. Hence, these aspects bode well for the growth of the chronic kidney disease drugs market.
  • The Centers for Disease Control and Prevention (CDC) estimated that nearly 37 mn American adults suffered from chronic kidney disease in 2019. These statistics are alarming. Thus, to cure a large number of people from this disease, the demand for chronic kidney disease drugs has increased considerably.
  • New formulations for better and quick treatment are being developed through research and development activities. Strategic collaborations are also serving as growth-changers for the chronic kidney disease drugs market. Quick approvals for use from authorities like the FDA (Food and Drug Administration) will prove to be a considerable growth-generator for the chronic kidney disease drugs market.
  • The COVID-19 pandemic has a minimal negative effect on the chronic kidney disease drugs market as it is exempted from the strict lockdown restrictions and can function with full capacity. Hence, the outbreak will not have a major impact on the growth of the chronic kidney disease drugs market.

Global Chronic Kidney Disease (CKD) Drugs Market: Overview

This report on the global chronic kidney disease (CKD) drugs market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2014 to 2024, considering the macro and micro environmental factors. Growth rates for each segment within the global chronic kidney disease (CKD) drugs market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also provide insights into the key trends of the chronic kidney disease (CKD) drugs market such as novel treatment approaches such as monoclonal antibodies, RNA-based therapies and stem cell based therapies. The key market indicators influencing global Chronic Kidney Disease (CKD) Drugs market taken into consideration including cost constraints and regulatory landscape. The report also includes market attractiveness analysis of the major segments that provides a thorough analysis of the overall competitive scenario in the global Chronic Kidney Disease (CKD) Drugs market. The report also highlights key events of the global Chronic Kidney Disease (CKD) Drugs industry. A porter’s five force analysis highlighting competitive landscape is also included in the report.

Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year. The year on year growth of global Chronic Kidney Disease (CKD) Drugs market for each segment is also reflected. Additionally, market related factors such as increasing preference for product innovation, and cost reduction for hospitals and greater affordability for patients in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Global Chronic Kidney Disease (CKD) Drugs Market: Segmentation

Based on product type, the global Chronic Kidney Disease (CKD) Drugs market has been segmented into ACE Inhibitors, Angiotensin-II receptor blockers, Calcium channel blockers, Beta blockers, Erythropoiesis-stimulating agents (ESAs), Diuretics, and Others. Based on end-user, the market has been segmented into hospitals and specialty clinics. Hospitals segment is expected to remain dominant during the forecast period.

Geographically, the global Chronic Kidney Disease (CKD) Drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented into major countries from each region. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Australia, India, Japan, Brazil, and Mexico.

Global Chronic Kidney Disease (CKD) Drugs Market: Competitive Landscape

The report also profiles major players in the Chronic Kidney Disease (CKD) Drugs market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. A thorough market share analysis of major companies operating in the Chronic Kidney Disease (CKD) Drugs market is provided in the report. Key companies profiled in the report include Keryx Biopharmaceuticals, Inc., Kissei Pharmaceutical Co., Ltd, AbbVie, Inc., GlaxoSmithKline plc., Sanofi S.A. , F. Hoffmann-La Roche Ltd., Pfizer, Inc., AstraZeneca plc, Amgen Inc., and Teva Pharmaceutical Industries Ltd.

The global Chronic Kidney Disease (CKD) Drugs market has been segmented as follows:

By Drug class

  • ACE Inhibitors
  • Angiotensin-II receptor blockers
  • Calcium channel blockers
  • Beta blockers
  • Erythropoiesis-stimulating agents (ESAs)
  • Diuretics
  • Others

By End User

  • Hospitals
  • Specialty Clinics

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Australia
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of Middle East & Africa

Section 1 Preface 
1.1 Report Scope and Market Segmentation 
1.2 Research Highlights

Section 2 Assumptions and Research Methodology 
2.1 Assumptions
2.2 Research Methodology

Section 3 Executive Summary
3.1 Global Chronic Kidney Disease (CKD) Drugs: Market Snapshot
3.2 Market Share Analysis by Region, 2015
3.3 Global Chronic Kidney Disease (CKD) Drugs Market: Opportunity Map

Section 4 Market Overview
4.1 Market Overview
4.2 Global Chronic Kidney Disease (CKD) Drugs Market: Market Indicators
4.3 Global Chronic Kidney Disease (CKD) Drugs Market: Market Outlook

Section 5 Pipeline Analysis
5.1 Chronic Kidney Disease (CKD) Drugs Market: Recent Approvals
5.2 Chronic Kidney Disease (CKD) Drugs Market: Pipeline Analysis
5.3 Global Chronic Kidney Disease (CKD) Pipeline Drugs Market Size (US$ Mn) Forecast, 2018–2024

Section 6 Market Dynamics
6.1 Drivers and Restraints Snapshot Analysis
6.2 Drivers
      6.2.1 High prevalence of chronic kidney disease (CKD) worldwide
      6.2.2 Promising pipeline and approval of novel molecules
      6.2.3 Shift toward value-based health care model
      6.2.4 Rise in incidence of cardiovascular disorders and diabetes
      6.2.6 Increase in health care spending & improvement in health care infrastructure
      6.2.6 Increase in global geriatric population
6.3 Restraints
      6.3.1 Competition from biosimilars due to patent loss
      6.3.2 Increase in preference for generic drug variants
      6.3.3 Change in reimbursement scenario 
6.4 Opportunities
      6.4.1 Focusing on emerging markets
      6.4.2 Novel therapeutic approaches such as stem cell therapy
6.5 Key Trends
6.6 Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, 2014–2024
6.7 Global Chronic Kidney Disease Drugs Market: Porter’s Analysis 

Section 7 Chronic Kidney Disease (CKD) Drugs Market Analysis, by Drug Class
7.1 Introduction
7.2 Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class
7.3 Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class 
      7.3.1 ACE Inhibitors
      7.3.2 Angiotensin-II Receptor Blockers
      7.3.3 Calcium Channel Blockers
      7.3.4 Beta Blockers
      7.3.5 Erythropoiesis-stimulating Agents (ESAs)
      7.3.6 Diuretics
      7.3.7 Others
7.5 Market Attractiveness Analysis, by Drug Class

Section 8 Chronic Kidney Disease (CKD) Drugs Market Analysis, by End-user
8.1 Introduction
8.2 Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End-user
8.3 Chronic Kidney Disease (CKD) Drugs Market Forecast, by End-user
      8.3.1 Hospitals
      8.3.2 Specialty Clinics
8.4 Market Attractiveness Analysis, by End-user

Section 9 Chronic Kidney Disease (CKD) Drugs Market Analysis, by Region
9.1 Global Chronic Kidney Disease (CKD) Drugs Market Snapshot, by Country
9.2 Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Region
9.3 Chronic Kidney Disease (CKD) Drugs Market Forecast, by Region
9.4 Market Attractiveness Analysis, by Region

Section 10 North America Chronic Kidney Disease (CKD) Drugs Market Analysis
10.1 Market Overview
10.2 Market Analysis, by Drug Class
      10.2.1 Market Value Share Analysis, by Drug Class
      10.2.2 Market Size (US$ Mn) Forecast, by Drug Class
              10.2.2.1 ACE Inhibitors
              10.2.2.2 Angiotensin-II Receptor Blockers
              10.2.2.3 Calcium Channel Blockers
              10.2.2.4 Beta Blockers
              10.2.2.5 Erythropoiesis-stimulating Agents (ESAs)
              10.2.2.6 Diuretics
              10.2.2.7 Others
10.3 Market Analysis, by End-user
      10.3.1 Market Value Share Analysis, by End-user
      10.3.2 Market Size (US$ Mn) Forecast, by End-user
              10.3.2.1 Hospitals
              10.3.2.2 Specialty Clinics
10.4 Market Analysis, by Country
      10.4.1 Market Value Share Analysis, by Country
      10.4.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
              10.4.2.1 U.S.
              10.4.2.2 Canada
10.5 Market Attractiveness Analysis
      10.5.1 by Drug Class 
10.5.2 by End-user
10.5.3 by Country

Section 11 Europe Chronic Kidney Disease (CKD) Drugs Market Analysis
11.1 Market Overview
11.2 Market Analysis, by Drug Class
      11.2.1 Market Value Share Analysis, by Drug Class
      11.2.2 Market Size (US$ Mn) Forecast, by Drug Class
              11.2.2.1 ACE Inhibitors
              11.2.2.2 Angiotensin-II Receptor Blockers
              11.2.2.3 Calcium Channel Blockers
              11.2.2.4 Beta Blockers
              11.2.2.5 Erythropoiesis-stimulating Agents (ESAs)
              11.2.2.6 Diuretics
              11.2.2.7 Others
11.3 Market Analysis, by End-user
      11.3.1 Market Value Share Analysis, by End-user
      11.3.2 Market Size (US$ Mn) Forecast, by End-user
              11.3.2.1 Hospitals
              11.3.2.2 Specialty Clinics
11.4 Market Analysis, by Country
      11.4.1 Market Value Share Analysis, by Country
      11.4.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
              11.4.2.1 U.K.
              11.4.2.2 Germany
              11.4.2.3 France
              11.4.2.4 Spain
              11.4.2.5 Italy
              11.4.2.6 Rest of Europe
11.5 Market Attractiveness Analysis
      11.5.1 by Drug Class 
      11.5.2 by End-user
      11.5.3 by Country

Section 12 Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Analysis
12.1 Market Overview
12.2 Market Analysis, by Drug Class
      12.2.1 Market Value Share Analysis, by Drug Class
      12.2.2 Market Size (US$ Mn) Forecast, by Drug Class
              12.2.2.1 ACE Inhibitors
              12.2.2.2 Angiotensin-II Receptor Blockers
              12.2.2.3 Calcium Channel Blockers
              12.2.2.4 Beta Blockers
              12.2.2.5 Erythropoiesis-stimulating Agents (ESAs)
              12.2.2.6 Diuretics
              12.2.2.7 Others
12.3 Market Analysis, by End-user
      12.3.1 Market Value Share Analysis, by End-user
      12.3.2 Market Size (US$ Mn) Forecast, by End-user
              12.3.2.1 Hospitals
              12.3.2.2 Specialty Clinics
12.4 Market Analysis, by Country
      12.4.1 Market Value Share Analysis, by Country
      12.4.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
              12.4.2.1 China
              12.4.2.2 Japan
              12.4.2.3 Australia
              12.4.2.4 India
              12.4.2.5 Rest of Asia Pacific
12.5 Market Attractiveness Analysis
      12.5.1 by Drug Class 
      12.5.2 by End-user
      12.5.3 by Country

Section 13 Latin America Chronic Kidney Disease (CKD) Drugs Market Analysis
13.1 Market Overview
13.2 Market Analysis, by Drug Class
      13.2.1 Market Value Share Analysis, by Drug Class
      13.2.2 Market Size (US$ Mn) Forecast, by Drug Class
              13.2.2.1 ACE Inhibitors
              13.2.2.2 Angiotensin-II Receptor Blockers
              13.2.2.3 Calcium Channel Blockers
              13.2.2.4 Beta Blockers
              13.2.2.5 Erythropoiesis-stimulating Agents (ESAs)
              13.2.2.6 Diuretics
              13.2.2.7 Others
13.3 Market Analysis, by End-user
      13.3.1 Market Value Share Analysis, by End-user
      13.3.2 Market Size (US$ Mn) Forecast, by End-user
              13.3.2.1 Hospitals
              13.3.2.2 Specialty Clinics
13.4 Market Analysis, by Country
      13.4.1 Market Value Share Analysis, by Country
      13.4.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
              13.4.2.1 Brazil
              13.4.2.2 Mexico
              13.4.2.3 Rest of LATAM
13.5 Market Attractiveness Analysis
      13.5.1 by Drug Class 
      13.5.2 by End-user
      13.5.3 by Country

Section 14 Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Analysis
14.1 Market Overview
14.2 Market Analysis, by Drug Class
      14.2.1 Market Value Share Analysis, by Drug Class
      14.2.2 Market Size (US$ Mn) Forecast, by Drug Class
              14.2.2.1 ACE Inhibitors
              14.2.2.2 Angiotensin-II Receptor Blockers
              14.2.2.3 Calcium Channel Blockers
              14.2.2.4 Beta Blockers
              14.2.2.5 Erythropoiesis-stimulating Agents (ESAs)
              14.2.2.6 Diuretics
              14.2.2.7 Others
14.3 Market Analysis, by End-user
      14.3.1 Market Value Share Analysis, by End-user
      14.3.2 Market Size (US$ Mn) Forecast, by End-user
              14.3.2.1 Hospitals
              14.3.2.2 Specialty Clinics
14.4 Market Analysis, by Country
      14.4.1 Market Value Share Analysis, by Country
      14.4.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
              14.4.2.1 South Africa
              14.4.2.2 Saudi Arabia
              14.4.2.3 Rest of MEA
14.5 Market Attractiveness Analysis
      14.5.1 by Drug Class 
      14.5.2 by End-user
      14.5.3 by Country

Section 15 Company Profiles
15.1 Chronic Kidney Disease (CKD) Drugs Market Share Analysis, by Company (2015)
15.2 Company Profiles
      15.2.1 Keryx Biopharmaceuticals, Inc. 
              15.2.1.1 Company Overview (HQ, Business Segments, Employee Strength)
              15.2.1.2 Financial Overview
              15.2.1.3 Product Portfolio
              15.2.1.4 SWOT Analysis
              15.2.1.5 Strategic Overview
      15.2.2 Kissei Pharmaceutical Co., Ltd
              15.2.2.1 Company Overview (HQ, Business Segments, Employee Strength)
              15.2.2.2 Financial Overview
              15.2.2.3 Product Portfolio
              15.2.2.4 SWOT Analysis
              15.2.2.5 Strategic Overview
      15.2.3 AbbVie, Inc.
              15.2.3.1 Company Overview (HQ, Business Segments, Employee Strength)
              15.2.3.2 Financial Overview
              15.2.3.3 Product Portfolio
              15.2.3.4 SWOT Analysis
              15.2.3.5 Strategic Overview
      15.2.4 GlaxoSmithKline plc.
              15.2.4.1 Company Overview (HQ, Business Segments, Employee Strength)
              15.2.4.2 Financial Overview
              15.2.4.3 Product Portfolio
              15.2.4.4 SWOT Analysis
              15.2.4.5 Strategic Overview
      15.2.5 Sanofi S.A. 
              15.2.5.1 Company Overview (HQ, Business Segments, Employee Strength)
              15.2.5.2 Financial Overview
              15.2.5.3 Product Portfolio
              15.2.5.4 SWOT Analysis
              15.2.5.5 Strategic Overview
      15.2.6 F. Hoffmann-La Roche Ltd. 
              15.2.6.1 Company Overview (HQ, Business Segments, Employee Strength)
              15.2.6.2 Financial Overview
              15.2.6.3 Product Portfolio
              15.2.6.4 SWOT Analysis
              15.2.6.5 Strategic Overview
      15.2.7 Pfizer, Inc. 
              15.2.7.1 Company Overview (HQ, Business Segments, Employee Strength)
              15.2.7.2 Financial Overview
              15.2.7.3 Product Portfolio
              15.2.7.4 SWOT Analysis
              15.2.7.5 Strategic Overview
      15.2.8 AstraZeneca plc
              15.2.8.1 Company Overview (HQ, Business Segments, Employee Strength)
              15.2.8.2 Financial Overview
              15.2.8.3 Product Portfolio
              15.2.8.4 SWOT Analysis
              15.2.8.5 Strategic Overview
      15.2.9 Amgen Inc. 
              15.2.9.1 Company Overview (HQ, Business Segments, Employee Strength)
              15.2.9.2 Financial Overview
              15.2.9.3 Product Portfolio
              15.2.9.4 SWOT Analysis
              15.2.9.5 Strategic Overview
      15.2.10 Teva Pharmaceutical Industries Ltd. 
              15.2.10.1 Company Overview (HQ, Business Segments, Employee Strength)
              15.2.10.2 Financial Overview
              15.2.10.3 Product Portfolio
              15.2.10.4 SWOT Analysis
              15.2.10.5 Strategic Overview

List of Tables

Table 01: Global Chronic Kidney Disease (CKD) Pipeline Drugs Market Size (US$ Mn) Forecast, 2018–2024
Table 02: Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 03: Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2016–2024
Table 04: Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Region, 2016–2024
Table 05: North America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 06: North America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2016–2024
Table 07: North America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 08: Europe Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 09: Europe Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2016–2024
Table 10: Europe Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 11: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 12: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2016–2024
Table 13: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 14: Latin America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 15: Latin America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 16: Latin America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 17: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 18: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 19: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024

List of Figures

Figure 01: Global Parsabiv (Etelcalcitide) Market Revenue, 2018 – 2024 (US$ Mn)
Figure 02: Global Forxiga (Dapagliflozin Market Revenue, 2021 – 2024 (US$ Mn)
Figure 03: Global Roxadustat (FG-4592) Market Revenue, 2018 – 2024 (US$ Mn)
Figure 04: Global Daprodustat Market Revenue, 2020 – 2024 (US$ Mn)
Figure 05: Global Vadadustat Market Revenue, 2020 – 2024 (US$ Mn)
Figure 06: Global Alpharen Market Revenue, 2020 – 2024 (US$ Mn)
Figure 07: Global Chronic Kidney Disease Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 08: Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 09: Global ACE Inhibitors Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 10: Global Angiotensin-II Receptor Blockers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 11: Global Calcium Channel Blockers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 12: Global Beta Blockers Market Revenue (US$ Mn) and Y-o-Y Growth (%) 2014–2024
Figure 13: Global Erythropoiesis-stimulating agents (ESAs) Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 14: Global Diuretics Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 15: Global Other Drug Class Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 16: Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Drug Class
Figure 17: Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End-user, 2016 and 2024
Figure 18: Global Hospitals Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 19: Global Specialty Clinics Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 20: Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by End-user
Figure 21: Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Region, 2016 and 2024
Figure 22: Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Region
Figure 23: North America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2024
Figure 24: North America Market Attractiveness Analysis, by Country
Figure 25: North America Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 26: North America Market Value Share Analysis, by End-user, 2016 and 2024
Figure 27: North America Market Value Share Analysis, by Country, 2016 and 2024
Figure 28: North America Market Attractiveness Analysis, by Drug Class 
Figure 29: North America Market Attractiveness Analysis, by End-user
Figure 30: Europe Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2024
Figure 31: Europe Market Attractiveness Analysis, by Country
Figure 32: Europe Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 33: Europe Market Value Share Analysis, by End-user, 2016 and 2024
Figure 34: Europe Market Value Share Analysis, by Country, 2016 and 2024
Figure 35: Europe Market Attractiveness Analysis, by Drug Class
Figure 36: Europe Market Attractiveness Analysis, by End-user
Figure 37: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2014–2024
Figure 38: Asia Pacific Market Attractiveness Analysis, by Country
Figure 39: Asia Pacific Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 40: Asia Pacific Market Value Share Analysis, by End-user, 2016 and 2024
Figure 41: Asia Pacific Market Value Share Analysis, by Country, 2016 and 2024
Figure 42: Asia Pacific Market Attractiveness Analysis, by Drug Class
Figure 43: Asia Pacific Market Attractiveness Analysis, by End-user
Figure 44: Latin America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2014–2024
Figure 45: Latin America Market Attractiveness Analysis, by Country
Figure 46: Latin America Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 47: Latin America Market Value Share Analysis, by End-user, 2016 and 2024
Figure 48: Latin America Market Value Share Analysis, by Country, 2016 and 2024
Figure 49: Latin America Market Attractiveness Analysis, by Drug Class
Figure 50: Latin America Market Attractiveness Analysis, by End-user
Figure 51: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2014–2024
Figure 52: Middle East & Africa Market Attractiveness Analysis, by Country
Figure 53: Middle East & Africa Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 54: Middle East & Africa Market Value Share Analysis, by End-user, 2016 and 2024
Figure 55: Middle East & Africa Market Value Share Analysis, by Country, 2016 and 2024
Figure 56: Middle East & Africa Market Attractiveness Analysis, by Drug Class
Figure 57: Middle East & Africa Market Attractiveness Analysis, by End-user
Figure 58: Global Chronic Kidney Disease (CKD) Drugs Market Share Analysis, by Company (2015)

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Chronic Kidney Disease (CKD) Drugs Market